Vericel (VCEL)

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.

Company profile

Ticker

VCEL

Exchange

NASDAQ

Website

vcel.com

CEO

Dominick Colangelo

Incorporated

Michigan

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...

Former names

AASTROM BIOSCIENCES INC

SEC CIK

0000887359

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Marrow Donation, LLC • Vericel Denmark ApS • Vericel Security Corporation ...

IRS number

943096597

VCEL stock data

1M 1Y 5Y

News

From Benzinga Pro

Looking Into Vericel's Return On Capital Employed

10 Aug 22

FDA Accepts MediWound's Refiling For Severe Thermal Burns Therapy For Review

3 Aug 22

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.

Vericel: Q2 Earnings Insights

3 Aug 22

Vericel (NASDAQ:VCEL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

MediWound Announces U.S. FDA Acceptance Of Biologics License Application For NexoBrid For The Treatment Of Severe Thermal Burns

3 Aug 22

Earnings Scheduled For August 3, 2022

3 Aug 22

Press releases

From Benzinga Pro

Vericel Reports Second Quarter 2022 Financial Results

3 Aug 22

Second Quarter Total Net Revenue of $37.0 Million MACI Net Revenue of $28.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation

MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

3 Aug 22

YAVNE, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) ("MediWound"), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and

Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel

21 Jul 22

Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body surface area of 56%) had successful engraftment of Epicel after one or two applications90% survival

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

3 Aug 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart VCEL financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	62.24M	62.24M	62.24M	62.24M	62.24M	62.24M
Cash burn (monthly)	(no burn)	(no burn)	3.03M	1.43M	(no burn)	(no burn)
Cash used (since last report)	n/a	n/a	4.38M	2.06M	n/a	n/a
Cash remaining	n/a	n/a	57.86M	60.17M	n/a	n/a
Runway (months of cash)	n/a	n/a	19.1	42.2	n/a	n/a

Beta Read what these cash burn values mean

Financial data from Vericel earnings reports.

Recent insider trades

VCEL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jun 22	Lisa Wright	Common Stock	Option exercise	Acquire M	No	No	0	433	0	2,784
1 Jun 22	Lisa Wright	RSU Common Stock	Option exercise	Dispose M	No	No	0	433	0	867
29 Apr 22	Gilman Steven C	Common Stock	Sell	Dispose S	No	Yes	30.94	900	27.85K	5,200
27 Apr 22	Rubino Alan L	Common Stock	Option exercise	Acquire M	No	No	0	2,600	0	11,994
27 Apr 22	Rubino Alan L	Stock Option Common Stock	Grant	Acquire A	No	No	31.99	6,500	207.94K	6,500
27 Apr 22	Rubino Alan L	RSU Common Stock	Grant	Acquire A	No	No	0	2,600	0	2,600
27 Apr 22	Rubino Alan L	RSU Common Stock	Option exercise	Dispose M	No	No	0	2,600	0	0
27 Apr 22	Hagen Heidi	Common Stock	Option exercise	Acquire M	No	No	0	2,600	0	12,850
27 Apr 22	Hagen Heidi	Stock Option Common Stock	Grant	Acquire A	No	No	31.99	6,500	207.94K	6,500
27 Apr 22	Hagen Heidi	RSU Common Stock	Grant	Acquire A	No	No	0	2,600	0	2,600

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

VCEL institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	196	183	+7.1%
Opened positions	34	21	+61.9%
Closed positions	21	37	-43.2%
Increased positions	68	66	+3.0%
Reduced positions	71	69	+2.9%

13F shares	Current	Prev Q	Change
Total value	2.05B	2.05B	+0.1%
Total shares	55.82M	55.22M	+1.1%
Total puts	41K	78.1K	-47.5%
Total calls	30.9K	24.3K	+27.2%
Total put/call ratio	1.3	3.2	-58.7%

Largest owners	Shares	Value	Change
BLK Blackrock	7.11M	$271.57M	+0.5%
Brown Capital Management	6.11M	$233.54M	+5.5%
RTW Investments	4.02M	$153.55M	-11.1%
Alger Associates	3.2M	$0	0.0%
Vanguard	3M	$114.83M	-1.5%
STT State Street	2.94M	$112.46M	+4.7%
Fred Alger Management	2.76M	$105.36M	-13.9%
Conestoga Capital Advisors	2.6M	$99.25M	+54.7%
FHI Federated Hermes	1.62M	$62.1M	-23.3%
MCQEF Macquarie	1.52M	$58.23M	-20.7%

Largest transactions	Shares	Bought/sold	Change
Conestoga Capital Advisors	2.6M	+918.3K	+54.7%
GW&K Investment Management	907.25K	+571.14K	+169.9%
RTW Investments	4.02M	-500K	-11.1%
FHI Federated Hermes	1.62M	-494.75K	-23.3%
Fred Alger Management	2.76M	-446.59K	-13.9%
MCQEF Macquarie	1.52M	-398.78K	-20.7%
MS Morgan Stanley	655.29K	+371.45K	+130.9%
Polar Asset Management Partners	0	-330.53K	EXIT
Brown Capital Management	6.11M	+320.31K	+5.5%
Fort Washington Investment Advisors	240.71K	+240.71K	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

ThermoGenesis • BioCardia • Athersys • Ocugen • Cellular Biomedicine • Regenicin • MyoKardia • Biostage • AVITA Medical

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: assessing, Bank, bear, borrow, borrower, borrowing, Chase, China, commodity, conflict, covenant, desired, educational, escalation, external, geopolitical, globe, impossible, inflation, inflationary, instability, invasion, JPMorgan, labor, leverage, likelihood, loan, magnify, outstanding, physician, ratio, recent, revolving, Russia, Russian, senior, SOFR, Ukraine, vast

Removed: administered, agency, emerged, fallen, learn, pathway, periodically, present, risen, sustained, transmission, updated, varied, world

From filing 10-Q 2022 Q2

Financial reports

View all